Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Marsh & McLennan Companies, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $352.72 (market cap $9.43B), while Marsh & McLennan Companies, Inc. trades at $188.67 (market cap $91.27B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 9.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Marsh & McLennan Companies, Inc. pays a 2.07% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | MRSH | |
|---|---|---|
Market Cap | $9.43B | $91.27B |
Sector | Health | Financials |
52-Week High | $356.25 | $211.21 |
52-Week Low | $241.71 | $157.32 |
Enterprise Value | $9.18B | $111.95B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Marsh & McLennan (MRSH) trades at $190.79, down 0.45% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat estimates with EPS of $2.96 versus $2.88 expected, driven by 6% revenue growth. The company announced the acquisition of Accel to expand Midwest operations, enhancing its insurance and consulting services. Valuation metrics show a P/E of 23.35 and ROE of 25.72%, reflecting robust profitability.
Outlook remains positive with a consensus price target of $202.89, offering ~6% upside. Risks include margin pressure from rising expenses and soft P&C pricing. Institutional activity is mixed, with Bank of America reducing its stake while others like Ashton Thomas Securities added positions. The stock presents a growth opportunity amid strategic expansions, though investors should monitor expense management and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
